TY  - GEN
AU  - Tebbe,U
AU  - Windeler,J
AU  - Boesl,I
AU  - Hoffmann,H
AU  - Wojcik,J
AU  - Ashmawy,M
AU  - Rüdiger Schwarz,E
AU  - von Loewis,P
AU  - Rosemeyer,P
AU  - Hopkins,G
TI  - Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase
SN  - 0735-1097
PY  - 1995///0817
KW  - Adult
KW  - Aged
KW  - Amino Acid Sequence
KW  - Confounding Factors, Epidemiologic
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Enzyme Precursors
KW  - therapeutic use
KW  - Female
KW  - Fibrinolytic Agents
KW  - Heparin
KW  - administration & dosage
KW  - Humans
KW  - Injections, Intravenous
KW  - Male
KW  - Middle Aged
KW  - Molecular Sequence Data
KW  - Myocardial Infarction
KW  - drug therapy
KW  - Recombinant Proteins
KW  - Thrombolytic Therapy
KW  - Time Factors
KW  - Treatment Outcome
KW  - Urokinase-Type Plasminogen Activator
KW  - Vascular Patency
KW  - drug effects
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/0735-1097(95)80008-5
ER  -